The state of Alabama currently has 15 active clinical trials seeking participants for Alzheimer's Disease research studies. These trials are conducted in various cities, including Birmingham, Mobile, Huntsville and Anniston.
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's diseas... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
11/18/2024
Locations: University of Alabama, Birmingham, Birmingham, Alabama
Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy
Recruiting
The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic amyloid deposition using the PET tracer \[C-11\]PiB in participants in the UAB Alzheimer's Disease Center cohort. Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with \[C-11\]PiB-PET, and cognitive status will be the primary outcome of this imaging study.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
10/08/2024
Locations: University of Alabama at Birmingham Medical Center, Birmingham, Alabama
Conditions: Alzheimer Disease
UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy
Recruiting
The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic tau deposition using the PET tracer AV-1451 in participants in the UAB-ADC cohort. The amount and distribution of AV-1451 in the brain will be correlated to demographic, clinical, genetic, and biospecimen data acquired through the separate ongoing UAB-ADC study. Assessment of interactions between race and vascular risk factors, brain tau levels measured with AV-1451-PET, and cogn... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
10/08/2024
Locations: UAB, Birmingham, Alabama
Conditions: Alzheimer Disease